The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Become an Insider to get the story behind the story — and before anyone else.
Subscribe to Continue Reading
Uh oh–you've read all five of your free articles for this month.
$179.95/yr US PRICE
Startup Aims to Treat Muscular Dystrophy with CRISPR
Patients groups are backing gene-editing as potential “home run” against disease.
Patent Office Hands Win in CRISPR Battle to Broad Institute
The dispute between researchers at UC Berkeley and the Broad Institute over the invention of the powerful gene-editing technique has been decided.
Companies Plan Tests of “Optogenetic Goggles” to Restore Sight
The visor-like devices need to be combined with gene therapy to work.